ARTICLE | Company News
AMAG, Endoceutics deal
February 17, 2017 4:45 PM UTC
Endoceutics granted AMAG exclusive, U.S. rights to commercialize Intrarosa prasterone. The product is approved to treat moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA), in postmenopausal women. AMAG expects to launch the drug in mid-2017...